Evidence map›Paper›PMID 40017229›Full record

ArticleAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica2025

An Evaluation Into the Robustness of Grading of Pleural Mesothelioma Outside of Specialist Centres.

Sarita Prabhakaran, Ashleigh J Hocking, Yazad Irani, Matthew Hussey, Andrey Alexeyenko, Katalin Dobra, Tamás Micsik, Edwina Duhig, Ann E Walts, Lieve Vanwalleghem and 8 more

Abstract read
In one paragraph

Article in APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sarita PrabhakaranDepartment of Anatomical Pathology, Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Adelaide, South Australia, Australia.ORCID https://orcid.org/0000-0003-3252-2519
Ashleigh J HockingDepartment of Anatomical Pathology, Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Adelaide, South Australia, Australia.
Yazad IraniDepartment of Anatomical Pathology, Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Adelaide, South Australia, Australia.
Matthew HusseyDepartment of Anatomical Pathology, Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Adelaide, South Australia, Australia.
Andrey AlexeyenkoScience for Life Laboratory, Solna, Sweden.
Katalin DobraDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Tamás MicsikDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Edwina DuhigSullivan Nicolaides Pathology, Brisbane, Queensland and John Flynn Private Hospital, Tugun, Queensland, Australia.
Ann E WaltsDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Lieve VanwalleghemDepartment of Pathology, AZ Sint Jan Bruges, Bruges, Belgium.
Vathana ChhutDepartment of Pathology, University of Health Sciences, Phnom Penh, Cambodia.
Anja C RodenDepartment of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Victor L RoggliDepartment of Pathology, Duke University Medical Center, Durham, North Carolina, USA.
Marjan HertoghsDepartment of Pathology, Network Hospitals GZA-ZNA, Antwerp, Belgium.
Francoise Galateau-SalleMESOPATH College Cancer Center Leon Berard, Lyon, France.
Luka BrcicMedical University of Graz, Diagnostic and Research Institute of Pathology, Graz, Austria.
David MoffatDepartment of Anatomical Pathology, Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Adelaide, South Australia, Australia.
Sonja KlebeDepartment of Anatomical Pathology, Flinders University, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Adelaide, South Australia, Australia.

Funding

Flinders University
6 · The paper itself

Abstract

The 2021 WHO classification of thoracic tumours recommends grading pleural mesothelioma to aid prognostication. Robustness of grading and morphological characterisation is key to its clinical utility, though validation of this grading system has largely been conducted by expert thoracic pathologists. We conducted a survey inviting pathologists across a range of practices and expertise to grade digitised images of 50 epithelioid pleural mesotheliomas that had been graded by an expert in thoracic pathology. We included slides that were considered potentially problematic such as small biopsies, focal necrosis, and rare subtypes that may affect grading (small cell and deciduoid features). Using the Sectra Uniview web viewer, participants were asked to score atypia, mitotic count, and necrosis and choose from a list of cytological and architectural features. Seventy-four pathologists anonymously participated. There was 90% agreement of consensus scores with expert opinion using the WHO 2-tier grade and 72% for the 3-tier nuclear grade but only 70% for nuclear atypia, 56% for mitoses, and 84% for necrosis. Both 3-tier nuclear grade and WHO 2-tier grading systems were significantly associated with survival. Our study affirms the overall robustness and utility of grading for pleural mesothelioma, reveals variances, and suggests the need for dedicated training.

Indexed as

MesotheliomaNeoplasm GradingPleural NeoplasmsFemaleHumansMaleMesothelioma, MalignantNecrosisPathologistsPrognosisSurveys and Questionnairesgrademesotheliomaprognosisvariability

Identifiers

PMID40017229
PMCPMC11868771

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.